ReviewCancers2024
MR-LINAC, a New Partner in Radiation Oncology: Current Landscape.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 23 citations in OpenAlex.
- Simultaneous T1, T2, R2*, PDFF, and triglyceride quantification in the head and neck using magnetic resonance fingerprinting on a 1.5T MR-Linac.Medical physics · 2026Article
- MR-Linac Successfully Guided the Treatment of a Free-Moving Mesenteric Mass.Precision radiation oncology · 2026Article
- A comparison of contrast-to-noise ratio of liver tumors between dynamic contrast-enhanced CT and respiration-tracked 4D-CT for radiotherapy targeting.The British journal of radiology · 2026Article
- Initial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Impact of intra- and interfractional motion on the dose distribution and urinary adverse events for magnetic resonance-guided prostate cancer radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging.Clinical and translational radiation oncology · 2026Article
- Patterns of response in head and neck cancer subregions using daily Quantitative MRI from MR-guided radiation therapy.Clinical and translational radiation oncology · 2026Article
- Long-term patient experience with online MR-guided radiotherapy: adaptive versus non-adaptive workflow.Frontiers in oncology · 2026Article
- Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025Review
- A global bibliometric and visualization study of the adaptive radiotherapy research landscape.Discover oncology · 2025Article
- First Spanish Experience with Stereotactic MR-Guided Adaptive Radiotherapy (SMART) in Borderline Resectable and Locally Advanced Pancreatic Cancer: A Prospective Study.Biomedicines · 2025Article
- Radiotherapy in Glioblastoma Multiforme: Evolution, Limitations, and Molecularly Guided Future.Biomedicines · 2025Review
- Application of respiratory motion management technology for patients with lung cancer treated with stereotactic body radiotherapy (Review).Oncology letters · 2025Review
- Partial Breast Irradiation for Early-Stage Breast Cancer: Advances, Challenges, and Future Directions-A Narrative Review.Tomography (Ann Arbor, Mich.) · 2025Review
- Prospective planning comparison of magnetic resonance-guided vs. internal target volume-based stereotactic body radiotherapy of hepatic metastases - Which patients do really benefit from an MR-linac?Clinical and translational radiation oncology · 2025Article
- Article
- Radiotherapy for primary bone tumors: current techniques and integration of artificial intelligence-a review.Frontiers in oncology · 2025Review
- MR beyond diagnostics at the ESMRMB annual meeting: MR theranostics and intervention.Magma (New York, N.Y.) · 2024Article
- Feasibility and Acute Toxicity of Hypo-Fractionated Radiotherapy on 0.35T MR-LINAC: The First Prospective Study in Spain.Cancers · 2024Article
- MR-Guided Adaptive Radiotherapy in Localized Prostate Cancer.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technological advances in radiation oncology are oriented towards improving treatment precision and tumor control. Among these advances, magnetic-resonance-image-guided radiation therapy (MRgRT) stands out, with technological advances to deliver targeted treatments adapted to a tumor's anatomy on the day while minimizing incidental exposure to organs at risk, offering an unprecedented therapeutic advantage compared to X-ray-based IGRT delivery systems. This new technology changes the traditional workflow in radiation oncology and requires an evolution in team coordination to administer more precise treatments. Once implemented, it paves the way for newer indication for radiation therapy to safely deliver higher doses than ever before, with better preservation of healthy tissues to optimize patient outcomes. In this narrative review, we assess the technical aspects of the novel linear accelerators that can deliver MRgRT and summarize the available published experience to date, focusing on oncological results and future challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.